A biotech company that created a way to create remote-controlled cells to repair damaged tissue using nanotechnology secures £200k investment.
MICA Biosystems controls the patient’s own stem cells in their body using nanotechnology to repair or replace damage or diseased tissue, through an out-patient procedure where just two needles and a take-home bandage (to be worn a couple of hours a day) is all it takes.
The money is from a £25m InnovateUK scheme which supports cutting-edge innovation in Great Britain, and will be used by the Birmingham-based tech firm to partner up with The Royal Orthopaedic Hospital to take the next step in making the treatment available to patients.
“InnovateUK is a fund which aims to propel forward world-changing innovation, developed and based in the UK. It provides a springboard to technologies which are a step-change from the status quo or the competition, and we’re glad we are recognised as such. We conducted extensive preclinical research and are working to begin the clinical trials to start improving the lives of millions of people across the world,” explained Dr. Mike Zurawski, the 26-year-old Chief Executive Officer of MICA Biosystems.
The female-founded company was started by world-class scientists in the field of regenerative medicine, and we aim to not only add years to the lives of patients, but add life to their years by significantly improving their quality of life.
“Stem cells have long been seen as having huge potential in medicine- they’re effectively a cell which can change itself to a specific tissue. Think of a block of clay, which can be shaped into a specific type of pottery before it’s fired. However, doctors have had no way of controlling this shaping process, leaving it up to the environment of the cell- essentially up to chance. This is what we’re changing- giving the medical teams the ability to remotely control what the cell is going to be shaped into, all while it’s already in place. We’re first looking at spinal repair, but we have plans to treat arthritis, tendon and ligament damage, strengthen and repair bone, and even aim to treat some neurodegenerative diseases and spinal cord damage.”
This newest cash injection brings the funding total to £3.5m to date, with the aim to accelerate the bringing of this technology into clinical trials.
Sign up for our monthly newsletter of upcoming events, recently published insights and SEC updates.